Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.40 and traded as high as $4.58. Achieve Life Sciences shares last traded at $4.38, with a volume of 63,124 shares trading hands.
Analysts Set New Price Targets
A number of research analysts have commented on the company. Jonestrading initiated coverage on Achieve Life Sciences in a research report on Wednesday. They set a "buy" rating and a $20.00 price target for the company. Lake Street Capital lowered their price objective on shares of Achieve Life Sciences from $19.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, March 5th. Finally, Oppenheimer reiterated an "outperform" rating and set a $18.00 target price on shares of Achieve Life Sciences in a report on Monday, April 1st.
Get Our Latest Stock Report on ACHV
Achieve Life Sciences Stock Performance
The company has a market capitalization of $156.52 million, a P/E ratio of -2.97 and a beta of 1.32. The company's 50 day moving average is $4.41 and its 200-day moving average is $4.40. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 4.02.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its position in shares of Achieve Life Sciences by 75.6% in the 1st quarter. Tower Research Capital LLC TRC now owns 3,646 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 1,570 shares during the last quarter. HRT Financial LP purchased a new position in Achieve Life Sciences in the fourth quarter worth about $32,000. Morgan Stanley lifted its stake in shares of Achieve Life Sciences by 437.4% in the fourth quarter. Morgan Stanley now owns 13,547 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 11,026 shares in the last quarter. Madison Park Capital Advisors LLC purchased a new stake in shares of Achieve Life Sciences during the fourth quarter valued at approximately $41,000. Finally, Prelude Capital Management LLC bought a new stake in shares of Achieve Life Sciences during the second quarter valued at approximately $49,000. Institutional investors own 33.52% of the company's stock.
Achieve Life Sciences Company Profile
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Further Reading
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
